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Abstract
Neurotrophic factors (NTFs) hold potential as disease-modifying therapies for neurodegenerative disorders like Parkinson’s disease.
Glial cell line-derived neurotrophic factor (GDNF), cerebral dopamine neurotrophic factor (CDNF), and mesencephalic astrocyte-
derived neurotrophic factor (MANF) have shown neuroprotective and restorative effects on nigral dopaminergic neurons in various
animal models of Parkinson’s disease. To date, however, their effects on brain neurochemistry have not been compared using in vivo
microdialysis. We measured extracellular concentration of dopamine and activity of dopamine neurochemistry-regulating enzymes
in the nigrostriatal system of rat brain. NTFs were unilaterally injected into the striatum of intact Wistar rats. Brain microdialysis
experiments were performed 1 and 3 weeks later in freely-moving animals. One week after the treatment, we observed enhanced
stimulus-evoked release of dopamine in the striatum ofMANF-treated rats, but not in rats treated with GDNF or CDNF.MANF also
increased dopamine turnover. Although GDNF did not affect the extracellular level of dopamine, we found significantly elevated
tyrosine hydroxylase (TH) and catechol-O-methyltransferase (COMT) activity and decreased monoamine oxidase A (MAO-A)
activity in striatal tissue samples 1 week after GDNF injection. The results show that GDNF, CDNF, and MANF have divergent
effects on dopaminergic neurotransmission, as well as on dopamine synthetizing and metabolizing enzymes. Although the cellular
mechanisms remain to be clarified, knowing the biological effects of exogenously administrated NTFs in intact brain is an important
step towards developing novel neurotrophic treatments for degenerative brain diseases.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder which holds an unmet need for a curative treatment. It
is the most common degenerative brain disease after
Alzheimer’s disease affecting approximately 2–3% of the pop-
ulation over 65 years of age [1]. The essential neuropatholog-
ical hallmarks of PD are death of dopaminergic cell bodies in
the midbrain substantia nigra pars compacta and presence of
intraneuronal cytoplasmic aggregates containing misfolded α-
synuclein called Lewy bodies and Lewy neurites [2, 3]. The
characteristic parkinsonian motor symptoms, including brady-
kinesia, rigidity, resting tremor, and postural impairment, re-
sult from the degeneration of the nigrostriatal dopaminergic
neurons and resultant dopamine deficiency within the dorsal
striatum.
Neurotrophic factors (NTFs) are endogenous secretory pro-
teins which promote differentiation, maintenance, function,
and plasticity of the nervous system and help neurons to re-
cover after an injury [4–7]. Due to these trophic effects, NTFs
are considered as potential disease-modifying therapies for
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neurodegenerative disorders such as PD. Glial cell line-
derived neurotrophic factor (GDNF), cerebral dopamine neu-
rotrophic factor (CDNF), andmesencephalic astrocyte-derived
neurotrophic factor (MANF) have shown neuroprotective and
neurorestorative effects on lesioned dopaminergic neurons
in vitro and in various animal models of PD [8–18]. In
in vivo lesion models, these NTFs increase the survival of
midbrain dopamine cells and fibers and improve aberrant mo-
tor performance suggesting enhanced dopaminergic function.
However, if we want to look upon NTFs as a novel therapeutic
approach for PD, it is crucial to understand how exogenously
administered, non-physiological concentrations of NTFs influ-
ence the normal nigrostriatal neurochemistry and neurotrans-
mitter homeostasis.
GDNF is a distant member of the TGF-β superfamily of
growth factors and conveys its biological effects via receptor
tyrosine kinase RET as Airaksinen and Saarma have compre-
hensively reviewed [5]. GDNF has been shown to potentiate
the excitability of dopaminergic neurons and increase the re-
lease of dopamine in cell cultures and midbrain slices [19–22].
Intracranial administration of GDNF elevated stimulus-
evoked dopamine overflow in the striatum of rats and rhesus
monkeys [23–29]. However, the major limitation in the earlier
in vivo studies is that they have been conducted under general
anesthesia which is known to have marked effects on neuro-
transmission, inducing alterations in neuronal activity, neuro-
transmitter synthesis, release, reuptake, and metabolism [30,
31]. To the best of our knowledge, the ability of GDNF to alter
dopamine release in completely non-anesthetized animals has
not been studied before.
CDNF and MANF form an evolutionary conserved and
structurally distinct family of NTFs [6, 12, 13]. CDNF and
MANF are located intracellularly in the endoplasmic reticu-
lum (ER), but they can be also secreted from cells [32–34].
Their mechanism of action is still unclear, although growing
body of evidence suggests that CDNF and MANF play an
important role in the maintenance of protein homeostasis in
the ER and alleviate/regulate ER stress [35–41]. Thus far,
however, the effects of intracerebrally administrated CDNF
or MANF on dopaminergic neurotransmission in vivo have
remained unstudied.
It has been shown that an intrastriatal injection of GDNF as
well as long-term overexpression of GDNF downregulate ty-
rosine hydroxylase (TH), the rate-limiting enzyme in dopamine
biosynthesis, in the midbrain of adult rats without affecting the
total activity of the enzyme [42–44]. On the other hand, GDNF
administration has been reported to increase phosphorylation
of TH at Ser31 and Ser40—the serine residues controlling TH
activity [28, 42, 45, 46]. To date, nothing is known about the
effects of CDNF or MANF on TH activity, nor the effect of
GDNF on dopamine metabolizing enzymes catechol-O-meth-
yltransferase (COMT) and monoamine oxidases A and B
(MAO-A and MAO-B).
The aim of the present study was to elucidate the effects of
intrastriatally administrated GDNF, CDNF, and MANF pro-
teins on dopamine release within the dorsal striatum of intact
freely-moving rats. We also wanted to clarify the effect of a
single intrastriatal injection of GDNF, CDNF, and MANF on
in vivo activity of TH. Finally, based on the results of the
microdialysis experiments, we tested the hypothesis that
GDNF alters the activity of COMT, MAO-A, and MAO-B.
Our results revealed divergent changes in dopamine release
as well as in dopamine synthesis and metabolism after exoge-
nously administratedNTFs. This is highly relevant information
when regarding NTFs as novel therapeutic approaches for PD.
Materials and Methods
Experimental Animals
Male Wistar rats (RccHan:WIST, Harlan, the Netherlands),
weighing 230–490 g during stereotaxic surgery, were used
for all experiments. For microdialysis experiments, rats were
moved from group housing (3–4 animals) to individual test
cages (30 × 30 × 30 cm) after the surgery. Tap water and rat
chow (Tekland Global Diet, Harlan) were available ad libitum.
Rats were under a 12:12 h light-dark cycle (lights on at
6:20 am), at an ambient temperature of 20–22 °C.
Stereotaxic surgeries and experiments were performed during
daylight between 8:00 am and 6:00 pm. All animal experi-
ments were in accordance with the directive of the European
Parliament and of the Council on the protection of animals
used for scientific purposes (Directive 2010/63/EU of the
European Parliament and of the Council). Experiments were
approved by the National Animal Experiment Board of
Finland (ESLH-2009-05234/Ym-23 and ESAVI/198/
04.10.07/2014).
Neurotrophic Factors
Vehicle group received sterile phosphate-buffered saline
(PBS). Recombinant hGDNF (2 μg/μl, reconstituted with
Milli-Q® water according to the manufacturer’s instructions)
was produced in E. coli bacterial cells (ProSpec-Tany
TechnoGene Ltd., Israel). The purity of GDNF was greater
than 95% as determined by SDS-PAGE electrophoresis and
RP-HPLC. GDNF was tested by the manufacturer to be com-
pliant for cell culture use in terms of lipopolysaccharide
(LPS) counts in the protein sample. Recombinant hCDNF
(2 μg/μl, in PBS) was produced in Spodoptera frugiperda
(Sf9) insect cells (Biovian Oy, Finland) and recombinant
hMANF (2 μg/μl, in PBS) in Chinese Hamster Ovary
(CHO) mammalian cells (Icosagen AS, Estonia). Both
CDNF and MANF were purified from serum-free cell super-
natant using ion-exchange chromatography. The purity of
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CDNF and MANF was greater than 95% as determined by
SDS-PAGE electrophoresis and mass-spectrometry.
Stereotaxic Surgery
Stereotaxic surgeries were performed under isoflurane (Attane
Vet 1000mg/g, Piramal Healthcare, UK) anesthesia (3.5–4.5%
during induction and 2.0–3.5% during maintenance). Rats
were fixed on a stereotaxic frame (Stoelting Co., IL, USA),
and the skull was exposed. Lidocaine-adrenalin solution
(10 mg/ml, Orion Pharma Oyj, Finland) was used for local
anesthesia and to prevent bleeding. A burr hole was made
using a high-speed dental drill (Foredom SR, The Foredom
Electric Co., CT, USA). A unilateral injection of GDNF,
CDNF, or MANF (10 μg in 5 μl) or PBS as vehicle (5 μl)
was made into the left dorsal striatum (A/P + 1.0; M/L + 2.7;
D/V − 5.0 relative to the bregma, according to the rat brain
atlas [47]) using an electronic microinjector (Quintessential
stereotactic injector, Stoelting) and a 10-μl microsyringe
(Hamilton Company, NV, USA) with a 26 gauge blunt tapered
needle. The injection rate was set to 1 μl/min. At the comple-
tion of the injection, the needle was kept in place for 4 min to
minimize backflow of the solution. For the microdialysis ex-
periments, a guide cannula (BASi MD-2250, Bioanalytical
Systems Inc., IN, USA) was implanted right after the NTF or
vehicle injection. The tip of the cannula was lowered into the
left dorsal striatum (A/P + 1.0; M/L + 2.7; D/V − 4.0 relative to
the bregma, according to the rat brain atlas [47]) after which the
cannula was attached to the skull with three stainless steel
screws and dental cement (Aqualox, Voco Cuxhaven GmbH,
Germany). To relieve postoperative pain, rats received trama-
dol 1 mg/kg s.c. (Tramal 50 mg/ml, Orion Pharma) at the end
of the surgery, and another similar injection 12 h later if need-
ed. After the surgery, rats were allowed to recover for 7 days
before the first microdialysis experiment.
Microdialysis
Microdialysis experiments were carried out in freely-moving
rats 1 and 3 weeks after the stereotaxic surgery. Before exper-
iments, all probes (BASi MD-2200, Bioanalytical Systems,
membrane length 2 mm) were tested for in vitro recovery at
room temperature to ensure their proper function. However,
in vivo dialysate concentrations were not corrected for in vitro
recoveries because corrected concentrations do not correlate
to true analyte concentrations in extracellular fluid [48].
In vitro recoveries of the probes for dopamine ranged from
7.3 to 19.1%. Before the experiments, there was a 2-h stabili-
zation period: the probe was inserted into the guide cannula,
and perfusion of the membrane was started with modified
Ringer solution (147 mM NaCl, 2.7 mM KCl, 1.2 mM
CaCl2, 1.0 mMMgCl2, 0.04 mM ascorbic acid) at a flow rate
of 2 μl/min. After the stabilization period, dialysate samples
were collected every 15 min for 270 min (Fig. 1b). The sam-
ples were analyzed right after collecting using a high-
performance liquid chromatography (HPLC) coupled with
an electrochemical detector as described below. Analyte con-
centrations in the first four samples (time points 15, 30, 45,
and 60 min) were used to calculate baseline levels (as aver-
ages) for dopamine and its main metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA). To stimulate dopamine release from nerve terminals,
two different stimulation solutions were administrated via re-
verse dialysis. First, the Ringer solution was changed into
100 mM potassium solution (27.5 mM NaCl, 100 mM KCl,
1.2 mM CaCl2, 1.0 mM MgCl2, 0.04 mM ascorbic acid) at
time point 15 min. This high-potassium solution was pumped
for 15 min after which it was changed back to the Ringer
solution. At time point 120 min, the Ringer solution was re-
placed with 100 μM D-amphetamine solution for 15 min.
After this, the Ringer solution was used until the end of the
experiment. The results were analyzed as percent changes of
the analyte concentrations compared to the corresponding
baseline levels. If the concentration of any analyte in the last
two baseline samples (time points 45 and 60 min) differed
more than 20% of the average, the rat was excluded from
the data. After the first microdialysis experiment, the probe
was removed from the brain. After the second experiment, rat
was sacrificed and the brain was excised and frozen on dry ice.
The correct placements of the microdialysis probes were ver-
ified histologically from 90-μm-thick coronal brain sections
which were cut with a sliding microtome (Leica CM3050,
Leica Instruments GmbH, Germany) and fixed on gelatin-
chrome-alume-coated microscope slides. Data only from the
rats with accurate probe placements in the dorsal striatum
were included in the analyses.
Quantification of Dopamine and Metabolites
from Microdialysis Samples
The analysis of samples collected in microdialysis experiments
and in in vitro recovery tests was performed with slight modifi-
cations from the methods described earlier [49, 50]. The con-
centrations of dopamine, DOPAC andHVA in the samples were
analyzed with a HPLC system equipped with an ESA
Coulochem II electrochemical detector and a model 5014B mi-
crodialysis cell (ESA Biosciences Inc., MA, USA). Dopamine
was reduced with an amperometric detector (potential −
100 mV) after being oxidized with a coulometric detector (+
300mV); DOPAC andHVAwere oxidizedwith the coulometric
detector. Dialysate samples of 25 μl were injected into the col-
umn (Kinetex C18, 2.6 μm, 100 Å, 50 × 4.6 mm; Phenomenex
Inc., CA, USA) with an autoinjector (Prominence, SIL-20 AC,
Shimadzu Co., Japan). The column was protected with
SecurityGuard Ultra filter (Phenomenex) and its temperature
was kept at 45 °C with a column heater (Croco-Cil, Cluzeau
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Info Labo, France). The mobile phase was a mixture of 0.1 M
NaH2PO4 buffer, pH 4.0, 100 mg/l octanesulphonic acid, ap-
proximately 5% (v/v) of methanol and 0.2 M ethylenediamine-
tetraacetic acid (EDTA). The flow rate of the mobile phase was
kept constant at 1.0 ml/min with an isocratic pump (Jasco PU-
2080 Plus, Jasco Co., Essex, UK) equipped with two pulse
dampers (SSI LP-21, Scientific Systems Inc., PA, USA). The
chromatograms were processed with chromatogram integration
software (Azur 4.0, Datalys, France).
In Vivo TH Activity Experiment
Seven days after an intrastriatal injection of NTFs (10 μg in
5 μl) or vehicle (5 μl), rats were administered with 3-
hydroxybenzylhydrazine (NSD1015) 100 mg/kg, i.p.
(Sigma-Aldrich Chemie GmbH, Germany) to inhibit aromat-
ic amino acid dopa decarboxylase (AADC) in the brain [51].
Rats were decapitated 30 min after the NSD1015 injection;
the brains were excised rapidly and rinsed with ice-cold phys-
iological saline solution. Dorsal striatum samples were col-
lected bilaterally from 2-mm coronal slices using an ice-
cooled rat brain matrix (Stoelting) and a 3-mm sample corer
(Fine Science Tools GmbH, Heildelberg, Germany) and fro-
zen immediately on dry ice. The samples were weighed and
homogenized with a sonicator (GM35-400, Rinco
Ultrasonics AG, Switzerland) in 500 μl of homogenization
solution consisting of six parts of 0.2 M HClO4 and one part
of antioxidant solution containing 1.0 mM oxalic acid, 0.1 M
Fig. 1 Design of the study and time course of the dopaminemicrodialysis
experiments. a All rats received an intrastriatal, unilateral injection of
GDNF, CDNF, MANF, or vehicle. One cohort of rats underwent
dopamine microdialysis experiments 1 and 3 weeks after the NTF
injection. Another cohort of rats was used to collect striatal tissue
samples for in vivo TH activity measurements 1 week after the NTF
treatment. NSD1015 (3-hydroxybenzylhydrazine) was administrated i.p.
to inhibit aromatic amino acid dopa decarboxylase in the brain 30 min
before tissue collection. From the third cohort of rats, striatal tissue sam-
ples were collected for ex vivo COMT and MAO activity measurements
1 week after the NTF treatment. b In the microdialysis experiments,
samples were collected every 15 min for 270 min. The first four samples
collected at 15, 30, 45, and 60 min were used to calculate baseline levels.
Then, dopamine release was stimulated via reverse dialysis of two differ-
ent stimulation solutions. First high-potassium (100 mM) perfusion solu-
tion was pumped for 15 min at time point 15 min (K+ administration)
which led to K+ response between time points 75 and 135 min. At time
point 120 min, amphetamine (100 μM)-containing perfusion solution
was pumped for 15 min (Amphet. administration) which led to amphet-
amine response between time points 180 and 255 min. The lag time
between the administration of a stimulation solution and the correspond-
ing response is due to slow flow rate of the perfusion solution (2 μl/min)
through microdialysis tubes which have to be long in case of freely-
moving animals (i.e., dead volume of the tubes is high)
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acetic acid, and 3.0 mM L-cysteine [52]. The homogenates
were centrifuged at 20,800×g for 35 min at 4 °C (Eppendorf
Centrifuge 5810R, Eppendorf AG, Germany). After the
centrifuging, 300 μl of the supernatant was moved into
Vivaspin® 500 filter concentrators (10,000 MWCO PES;
Sartorius Stedim Biotech GmbH, Germany) and centrifuged
again at 8600×g for 35 min at 4 °C. Filtrates containing
monoamines were analyzed with a HPLC system as de-
scribed below. The amount of L-3,4-dihydroxyphenylalanine
(L-DOPA) in the striatum samples was calculated as nano-
grams per gram (ng/g) wet weight of the sample for both
hemispheres.
Quantification of L-DOPA from Striatal Tissue
Samples
The concentration of L-DOPA in striatal tissue samples was
measured with a HPLC system as described earlier [53].
Samples of 100 μl were injected into the column (Kinetex
XD-C18, 2.6 μm, 100 Å, 100 × 4.6 mm; Phenomenex) with
an autoinjector (Prominence Auto Sampler, SIL-20 AC,
Shimadzu). The column temperature was kept at 45 °C with
a column heater (Croco-Cil). The mobile phase was a mixture
of 0.1 M NaH2PO4 buffer, pH 3.0, 150 mg/l octanesulfonic
acid 4% (v/v) of methanol. An isocratic pump (ESA Model
582 Solvent Delivery Module; ESA Biosciences) equipped
with a pulse damper (SSI LP-21, Scientific Systems) provided
a constant flow rate of 1.0 ml/min. The analytes were detected
with an electrochemical detector (ESA CoulArray Electrode
Array, ESA Biosciences), and the chromatograms were proc-
essed with an integration software (CoulArray for Windows,
ESA Biosciences).
Estimation of COMT and MAO Activities
COMT, MAO-A, and MAO-B enzyme activities were mea-
sured from striatum samples 7 days after an intrastriatal injec-
tion of GDNF (10 μg in 5 μl) or vehicle (5 μl). Rats were
decapitated, and the brains were excised rapidly and rinsed
with ice-cold physiological saline solution. Dorsal striatum
samples were collected bilaterally from 4-mm coronal slices
using an ice-cooled rat brain matrix (Stoelting) and a 3-mm
sample corer (Fine Science Tools) and frozen immediately on
dry ice. The samples were weighed and homogenized with a
sonicator (GM35-400, Rinco Ultrasonics) in 10 mM phos-
phate buffer (pH 7.4) in a volume of 20× wet weight of the
sample. The homogenates were centrifuged at 1000×g for
20 min at 4 °C (Eppendorf Centrifuge 5810R). Total protein
concentration was determined using bicinchoninic acid meth-
od (Pierce™ BCA Protein Assay Kit, Thermo Fisher
Scientific Inc., MA, USA).
Total COMT activity assay was performed as described
earlier [54, 55]. The enzyme suspension was incubated for
30 min at 37 °C in 100 mM phosphate buffer (pH 7.4)
containing 5 mM MgCl2, 200 μM S-adenosyl-L-
methionine (Sigma Chemical Co., MO, USA), and
500 μM 3,4-dihydroxybenzoic acid (Sigma). The reaction
was stopped by adding ice-cold 4 M perchloric acid.
Samples were centrifuged at 5530×g for 10 min at 4 °C
after which supernatant was filtered through 0.45-μm sy-
ringe filter (Millex®-HA, Millipore, Merck KGaA,
Darmstadt, Germany) and diluted 1:20 in 0.4 M perchloric
acid. The reaction products, vanillic and isovanillic acid,
were analyzed with a HPLC system equipped with an ESA
Coulochem II electrochemical detector (detector potential
+ 500 mV) and a model 5011A analytical cell (ESA
Biosciences). An autoinjector (Prominence SIL-20AC,
Shimadzu) was used to inject 10 μl of the samples into
the column (Spherisorb® ODS2, C18, 3 μm, 4.6 ×
100 mm; Waters Spherisorb, MA, USA). The column tem-
perature was kept at 35 °C with a column heater (Croco-
Cil). The mobile phase consisted of 0.1 M Na2HPO4 buffer
(pH 3.3), 0.15 mM EDTA and 25% methanol. The flow
rate of the mobile phase was set to 1.0 ml/min and kept
constant with an isocratic pump (Jasco PU-2080 Plus,
Jasco). The chromatograms were processed with an inte-
gration software (Azur 5.0, Datalys). Total COMT activity
was calculated as picomoles of vanillic acid formed in
1 minute per milligram of protein in the sample.
MAO-A and MAO-B activities were determined with
Monoamine Oxidase Assay Kit (MAK136, Sigma-
Aldrich) according to the manufacturer’s instructions. In
the assay, MAO-A and -B react with p-tyramine forming
H2O2 which is determined by a fluorimetric method. To
isolate MAO-A and MAO-B activities, isoform-specific
inhibitors were used: MAO-A activity was assayed by
adding 5 μM of MAO-A-specific inhibitor clorgyline into
the control well and subtracting the remaining MAO-B
activity from the total MAO activity in the sample well
without inhibitors. Likewise, MAO-B activity was assayed
by adding 5 μM of MAO-B-specific inhibitor pargyline
into the control well and subtracting the remaining MAO-
A activity from the total MAO activity. Black 96-well
plates with clear bottom were used in the assay. The fluo-
rescence of the samples and H2O2 standard curve was mea-
sured with a multi-well plate reader (Victor2, 1420
Multilabel Plate Reader, PerkinElmer Inc., MA, USA)
using an excitation wavelength of 530 nm and a detection
wavelength of 590 nm.
Statistical Analysis
Data from the microdialysis experiments were analyzed with
analysis of variance (ANOVA) for repeated measures follow-
ed by Ryan-Einot-Gabriel-Welsch F (REGWF) post hoc test.
One-way ANOVA followed by REGWF post hoc test was
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used to compare the differences in the baseline concentrations
between the treatment groups as well as to analyze results
from the in vivo TH activity experiment. Differences in the
baseline concentrations within the treatment groups 1 and
3 weeks after the surgery were analyzed with paired two-
tailed Student’s t test. Results from the COMT and MAO
activity experiments were analyzed with unpaired two-tailed
Student’s t tests. All analyses were conducted with SPSS®
Statistics 24 software (IBM SPSS Inc., IL, USA). Exclusion
criterion used in the data analyses was mean ± 2 × standard
deviation. Results are expressed as mean ± SEM and consid-
ered to be significant at p < 0.05.
Results
Unaltered Baseline Levels of Dopamine and Its
Metabolites After NTF Treatments
The effects of intrastriatally injected NTFs on dopamine re-
lease from nigrostriatal dopaminergic neurons were examined
in two consecutive microdialysis experiments, at 1 and
3 weeks after the stereotaxic surgery, in freely-moving rats.
The extracellular baseline levels of dopamine, DOPAC, or
HVA did not differ significantly between the treatment groups
either at 1 or 3 weeks after the surgery. However, the baseline
levels of dopamine and its metabolites were significantly low-
er in most of the treatment groups when measured at 3 weeks
after the surgery as compared with the concentrations mea-
sured at 1 week after the surgery (Table 1).
Elevated Stimulus-Evoked Release of Dopamine
in MANF-Treated Rats
To study the ability of NTFs to alter stimulus-evoked release
of dopamine in the striatum, dopaminergic nerve terminals
were first depolarized by administrating high concentration
of potassium via reverse dialysis which caused an extensive
increase in the extracellular concentration of dopamine in all
treatment groups (Fig. 2a, b). After a recovery period, admin-
istration of amphetamine through the microdialysis probe
drained dopaminergic vesicles and reversed the function of
dopamine transporter (DAT) in the nerve terminals [56], thus
inducing another notable increase in dopamine release.
One week after the surgery, potassium- and amphetamine-
evoked release of dopamine was significantly elevated in
MANF-treated rats as compared with the vehicle- and GDNF-
treated animals (ANOVA for repeated measures 75–135 min:
F3,36 = 4.874; p = 0.006; REGWF p < 0.05; 180–255 min:
F3,36 = 3.683; p = 0.021; REGWF p < 0.05) (Fig. 2a). In addi-
tion, extracellular dopamine concentration significantly differed
between the treatment groups during the whole experiment
(ANOVA for repeated measures 15–270 min: F3,36 = 4.678;
p = 0.007). According to REGWF’s post hoc test, the differ-
ences were between MANF- and vehicle-, MANF- and
GDNF-, and CDNF- and GDNF-treated animals (p < 0.05).
We also compared total potassium and amphetamine responses
between the treatment groups by analyzing average increase in
dopamine release during the stimulus responses (Fig. 2b). The
results from these analyses supported our findings: Average
potassium-evoked dopamine overflow was augmented in
MANF-treated rats as compared with the vehicle- and GDNF-
treated rats (one-way ANOVA F3,36 = 4.874; p = 0.006;
REGWF p < 0.05). Congruently, average amphetamine-
evoked dopamine overflow was augmented in MANF group
when compared to the vehicle and GDNF groups (one-way
ANOVA F3,36 = 3.683; p = 0.021; REGWF p < 0.05).
Three weeks after the surgery, we did not find statistically
significant differences between the treatment groups.
Figures showing microdialysis results at 3 weeks after the
surgery are presented in supplementary material (Fig. 5).
DOPAC concentration in the extracellular fluid de-
creased during the potassium and amphetamine responses
compared to the baseline level in all treatment groups as
reported earlier [57, 58] (Fig. 2c, supplementary material
Fig. 5b). Similarly, also HVA concentration decreased dur-
ing the potassium response but increased during the am-
phetamine response (Fig. 2d, supplementary material
Fig. 5c). No statistical differences, however, were observed
between the treatment groups in extracellular concentra-
tions of DOPAC or HVA.
Table 1 Dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and
homovanillic acid (HVA) concentrations (nM) in the baseline samples
at 1 and 3 weeks after the surgery. Baseline value for each analyte is
shown as average of the concentrations in the baseline samples (at time
points 15, 30, 45, and 60 min); mean ± SEM; at week 1, n = 10 in each
group; at week 3, n = 8–10 in each group
Week 1 Week 3
Mean SEM Mean SEM
Dopamine (nM) VEH 1.43 0.26 0.80 * 0.16
GDNF 1.54 0.47 0.52 0.10
CDNF 1.05 0.18 0.65 * 0.16
MANF 0.92 0.17 0.68 0.07
DOPAC (nM) VEH 539.61 59.97 464.43 72.36
GDNF 560.44 96.49 311.29 * 58.60
CDNF 553.02 56.58 385.77 * 60.50
MANF 620.39 47.10 443.76 * 42.34
HVA (nM) VEH 323.93 36.59 303.21 44.11
GDNF 475.58 88.83 238.65 ** 40.58
CDNF 351.30 43.21 252.38 * 37.90
MANF 368.47 28.70 293.61 * 32.18
*p < 0.05, **p < 0.01 (paired two-tailed Student’s t test, between week 1
and week 3 baseline concentrations)
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Increased Dopamine Turnover in MANF-Treated Rats
To study if NTFs were able to alter dopamine metabolism in
the striatum, we determined dopamine turnover by calculating
DOPAC/dopamine and HVA/dopamine ratios from the micro-
dialysis samples. Oneweek after the surgery,MANF produced
marked increase in dopamine turnover as evaluated by
DOPAC/dopamine ratio (Fig. 3a). The ratio was significantly
higher in MANF-treated rats as compared with the vehicle-
and GDNF-treated rats during the whole experiment
(ANOVA for repeated measures 15–270 min: F3,36 = 3.065;
p = 0.040; REGWF p < 0.05) as well as in the baseline samples
(ANOVA for repeatedmeasures 15–60min:F3,36 = 3.868; p =
0.017; REGWF p < 0.05). Three weeks after the surgery, there
were no differences between the treatment groups in DOPAC/
dopamine ratio (supplementary material Fig. 6a). We did not
see any significant differences in HVA/dopamine ratio be-
tween the treatment groups either 1 or 3 weeks after the sur-
gery (Fig. 3b, supplementary material Fig. 6b).
We also calculated the ratio of the metabolites from the
microdialysis samples. Unexpectedly, 1 week after the sur-
gery, DOPAC/HVA ratio was significantly reduced in
GDNF-treated rats compared to all the other treatment
groups during the whole experiment (ANOVA for repeated
Fig. 2 Extracellular striatal concentrations of dopamine and its main
metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) measured using brain microdialysis 1 week after an
intrastriatal injection of GDNF, CDNF, MANF, or vehicle. a In MANF-
treated rats, both potassium-evoked (75–135 min) and amphetamine-
evoked (180–255 min) release of dopamine was elevated when compared
to vehicle- and GDNF-treated rats. In addition, the overall (15–270 min)
extracellular dopamine concentration was elevated in MANF group com-
pared to vehicle and GDNF groups, and in CDNF group compared to
GDNF group (*p < 0.05 MANF vs. VEH and MANF vs. GDNF;
#p < 0.05 CDNF vs. GDNF; REGWF post hoc analysis after ANOVA
for repeated measures). b Average dopamine overflow during potassium
and amphetamine responses was augmented in MANF-treated rats when
compared to vehicle- and GDNF-treated rats (*p < 0.05 MANF vs. VEH
and MANF vs. GDNF; REGWF post hoc analysis after one-way
ANOVA). c, d NTFs did not have significant effects on extracellular
DOPAC or HVA concentration at 1 week after the injection. The period
when high-potassium and amphetamine perfusion solutions were
pumped (K+ and Amphet. administration) (a) and the period of potassium
and amphetamine responses (a, c, d) are depicted under the x-axes.
Results are shown as % of baseline value (= 100%); mean ± SEM; n =
10 in each group
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measures 15–270 min: F3,36 = 7.397; p = 0.001; REGWF
p < 0.05) (Fig. 3c). Three weeks after the surgery,
DOPAC/HVA ratio was still smaller in GDNF group than
in the other groups but the difference did not reach signif-
icance (ANOVA for repeated measures 15–270 min:
F3 ,32 = 2.537; p = 0.074) (supplementary material
Fig. 6c). The changed DOPAC/HVA ratio suggests that
GDNF injection alters the activity of dopamine metaboliz-
ing enzymes COMT and MAO.
Increased In Vivo TH Activity in Rats Treated
with GDNF
As we found elevated stimulus-evoked release of dopamine in
MANF-, but not in GDNF-, treated rats, we wanted to inves-
tigate the effect of the NTF injection on in vivo activity of TH.
To that end, we inhibited AADC enzyme in the brain with a
blood-brain barrier passing inhibitor NSD1015 1 week after
the NTF injection. Half an hour after AADC inhibition, we
collected tissue samples from the dorsal striatum and quanti-
fied accumulated L-DOPA in the samples. In this experiment,
the amount of L-DOPA accumulated into the striatum pro-
vides a direct measure for L-DOPA production rate, which
reflects the in vivo activity of phosphorylated and non-
phosphorylated TH in the nigrostriatal pathway [51].
GDNFwas able to increase TH activity as the amount of L-
DOPA in the treated striatum was increased approximately by
60% as compared with the vehicle (one-way ANOVA F3,22 =
3.780; p = 0.025; REGWF p < 0.05) (Fig. 4a). MANF also
tended to enhance the accumulation of L-DOPA (approxi-
mately by 50%) while CDNF had no effect. The amount of
L-DOPA in treated versus untreated striatum did not differ
within the treatment groups when compared with paired
two-tailed Student’s t test.
Increased COMT Activity and Reduced MAO Activity
in Rats Treated with GDNF
Because of the significantly reduced DOPAC/HVA ratio in
GDNF-treated rats, we decided to assess the effect of GDNF
on dopamine-metabolizing enzymes COMT, MAO-A, and
MAO-B. To study this, GDNF or vehicle was unilaterally
injected into the dorsal striatum and 1 week later, striatal tissue
samples were collected for ex vivo enzyme activity assays.
GDNF increased the total activity of COMT by 155% in
the treated striatum when compared to the vehicle-treated rats
(unpaired two-tailed Student’s t test t(13) = − 5.159;
p < 0.001) and by 170% when compared to the untreated
Fig. 3 Dopamine turnover analyzed 1 week after an intrastriatal injection
of GDNF, CDNF, MANF, or vehicle. DOPAC/dopamine, HVA/
dopamine, and DOPAC/HVA ratios were calculated as ratios of the ana-
lyte concentrations in the microdialysis samples. a DOPAC/dopamine
turnover was enhanced in MANF-treated rats as compared to the rats
treated with vehicle or GDNF during the whole experiment (15–
270 min) and during the baseline (15–60 min) (*p < 0.05 MANF vs.
VEH and MANF vs. GDNF; REGWF post hoc analysis after ANOVA
for repeated measures). b There were no significant changes in HVA/
dopamine turnover. c Less DOPAC was formed compared to HVA in
GDNF-treated rats as measured by DOPAC/HVA ratio which was signif-
icantly smaller in GDNF group than in the other treatment groups during
the whole experiment (15–270 min) (#p < 0.05 GDNF vs. VEH, GDNF
vs. CDNF and GDNF vs. MANF; REGWF post hoc analysis after
ANOVA for repeated measures). The period of potassium and amphet-
amine responses are depicted under the x-axes. Results are shown as
concentration ratios; mean ± SEM; n = 10 in each group
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striatum (paired two-tailed Student’s t test t(7) = 6.041;
p < 0.001) (Fig. 4b). GDNF also reduced MAO-A activity in
the treated striatum by 27% when compared to the vehicle-
treated controls (unpaired two-tailed Student’s t test t(14) =
2.944; p = 0.011) (Fig. 4c). GDNF had a modest reducing
effect on MAO-B activity (approximately 18% as compared
to the vehicle-treated controls), but the difference remained
insignificant (unpaired two-tailed Student’s t test t(14) =
1.689; p = 0.113) (Fig. 4d).
Discussion
Themain findings in this studywere as follows: (i) Intrastriatal
injection of MANF elevated stimulus-evoked release of dopa-
mine in the striatum 1 week after the injection. Elevated dopa-
mine release was accompanied by enhanced DOPAC/
dopamine turnover in MANF-treated rats. (ii) In GDNF-
treated rats, stimulus-evoked release of dopamine was not
changed although striatal TH activity was increased. At the
same time, DOPAC/HVA ratio was decreased apparently due
to increased COMT activity and decreased MAO-A activity.
To be able to assess different presynaptic release mecha-
nisms, we utilized a microdialysis protocol with two distinct
stimuli (high concentration of K+ and amphetamine) to evoke
dopamine release from nigrostriatal nerve endings. We saw
smaller differences in dopamine overflow between the treat-
ment groups during the amphetamine response than during the
potassium response (Fig. 2a). High concentration of potassi-
um depolarizes nerve terminals and causes fusion of vesicles
close to the presynaptic membrane in a calcium-dependent
manner [59]. This pool of presynaptic dopamine is considered
to be readily releasable. Amphetamine, on the contrary, is
known to deplete vesicular stores of dopamine and reverse
the function of DAT causing calcium independent release of
dopamine [56, 59]. Thus, amphetamine stimulus gives an
Fig. 4 Effect of NTF treatment on the activity of dopamine
neurochemistry-regulating enzymes. a In vivo TH activity was assayed
1 week after an intrastriatal injection of GDNF, CDNF,MANF, or vehicle
by collecting striatal tissue samples 30min after the inhibition of aromatic
amino acid dopa decarboxylase with NSD1015 (100 mg/kg, i.p.) and
analyzing the amount of accumulated L-DOPA in the samples. L-
DOPAwas synthetized more in rats treated with GDNF as compared to
the vehicle-treated rats which indicates increased TH activity in GDNF-
injected striata (*p < 0.05 GDNF vs. VEH; one-way ANOVA followed
by REGWF post hoc test). b–d Due to significantly reduced DOPAC/
HVA ratio in GDNF-treated rats seen in the microdialysis experiments,
the effect of GDNF on COMT, MAO-A, and MAO-B activity was
determined from striatal tissue samples collected 1 week after an
intrastriatal injection of GDNF or vehicle. b GDNF significantly in-
creased total COMT activity in the treated striatum as compared to the
vehicle-treated rats (**p < 0.001; unpaired two-tailed Student’s t test) as
well as compared to the untreated side (#p < 0.001; paired two-tailed
Student’s t test). c GDNF significantly reduced MAO-A activity in the
treated striatum as compared to the vehicle-treated rats (* p = 0.011; un-
paired two-tailed Student’s t test). dMAO-B activity was also reduced in
rats treated with GDNF but not significantly. Results are shown as mean
± SEM; in TH activity experiment, n = 6–7 in each group; in COMT and
MAO activity experiments, n = 7–8
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estimate of the total amount of dopamine stored in nerve ter-
minals. Our results may indicate that MANF can enhance the
dynamics of calcium mediated membrane fusion of presynap-
tic dopamine vesicles or increase the proportion of readily
releasable vesicles as demonstrated by elevated potassium-
evoked release of dopamine.
One week after the NTF injection, stimulus-evoked release
of dopamine was elevated in MANF-treated rats suggesting
increased sprouting of dopaminergic fibers (Fig. 2a). This may
not be the case, however, since Voutilainen et al. showed no
effect of 2-week intrastriatal infusion of MANF on TH-
immunoreactivity in the substantia nigra or striatum in intact
rats [15]. Thus, it is more likely that MANF enhances dopa-
minergic neurotransmission through presynaptic storage or
release mechanisms rather than through sprouting. For exam-
ple, GDNF has been proposed to facilitate synaptic transmis-
sion by modulating the quantal size of neurotransmitter re-
lease [19], potentiating Ca2+ influx [22, 60], and inhibiting
A-type K+-channels [21], thereby potentiating excitability of
neurons. It is possible that MANF has same type of modula-
tory effects on the function of nerve terminals although its
possible effects on ion channels still remain to be clarified.
Contrary to the previous studies, the stimulus-evoked re-
lease of dopaminewas not increased in GDNF-treated animals
[24–26, 28, 29]. The previous studies were conducted under
general anesthesia. Anesthetics are known to have marked
effects on neurotransmission which can explain the differing
results from the present study [30, 31]. Similarly to our results,
by using freely-moving rats with only a brief metofane anes-
thesia at the beginning of microdialysis experiment, Xu and
Dluzen did not see significant differences between GDNF-
and vehicle-injected rats [61]. In a microdialysis study with
freely-moving mice, potassium-evoked release of dopamine
did not differ between wild-type and MEN2B mice that have
constantly active RET [62]. These observations are in line
with our results. DAT activity has been shown to be markedly
increased in MEN2B mice and in GDNF hypermorphic mice
overexpressing GDNF [62, 63]. Therefore, it can be hypothe-
sized that in the present study, increased DAT activity after
GDNF treatment results in enhanced clearance of extracellular
dopamine after potassium-stimulus and thus nullifies the do-
paminergic transmission enhancing effect of GDNF. In addi-
tion, during amphetamine response, when dopamine reuptake
through DATand metabolism through MAO are inhibited, the
role of COMT in dopamine turnover is pronounced. As
GDNF was shown to increase COMT activity, it can be spec-
ulated that amphetamine-evoked dopamine release was di-
minished in GDNF-treated rats due to increased metabolism
through COMT.
Baseline concentration of dopamine and its metabolites
remained unchanged between the treatment groups at 1 and
3 weeks after the NTF injection (Table 1). This result is in line
with earlier microdialysis experiments: there were no
differences in the basal extracellular dopamine concentration
between GDNF- and vehicle-treated rats [24, 61] or between
MEN2B and wild-type mice [62]. The unchanged baseline
concentrations may result from effective homeostatic mecha-
nisms after NTF treatments, including enhanced uptake of
dopamine through DAT. It is also possible that dopamine is
stored more in terminal vesicles in NTF-treated animals, while
the tonic release of dopamine remains unchanged during the
baseline.
To study if the elevated release of dopamine in MANF-
injected rats was due to enhanced synthesis of dopamine, we
determined the effect of the NTFs on in vivo TH activity.
Because of the fact that unilaterally injected NTFs have bilat-
eral effects [42, 64, 65], we compared the amount of L-DOPA
only in the treated striata between the treatment groups. We
saw significantly increased TH activity in GDNF-treated rats,
measured as accumulated striatal L-DOPA following inhibi-
tion of AADC [51] (Fig. 4a). MANF also seemed to have an
increasing effect on TH activity, but this effect was not signif-
icant. Thus, TH activity cannot solely explain the significant
elevation in the stimulus-evoked dopamine release seen in
MANF-treated rats. The effect of GDNF on TH activity, on
the other hand, is in line with an earlier observation according
to which continuous RET activation in MEN2B mice in-
creases in vivo TH activity [62]. Although exogenous
GDNF has been shown to downregulate the total expression
of TH in dopamine neurons, it can also increase the phosphor-
ylation of TH and consequently the activity of the enzyme [28,
42–46]. Thus, the differences in TH activity between the treat-
ment groups can be due to different ability of NTFs to enhance
the phosphorylation of TH. The downregulation of TH after
GDNF administration may be a compensatory response to its
increased phosphorylation and activity. Increased TH activity
in GDNF-treated rats may also be due to decreased amount of
dopamine in nerve terminals which might affect the activity of
TH through feed-back mechanisms as speculated by
Georgievska et al. [44].
DOPAC/dopamine ratio was measured from the microdial-
ysis samples as an indicator of dopamine metabolism. The
turnover of dopamine into DOPAC was significantly in-
creased in MANF group as compared to vehicle and GDNF
groups 1 week after the NTF injection (Fig. 3a). Moreover,
HVA/dopamine turnover seemed to be increased in MANF
group but the differences were not statistically significant
(Fig. 3b). Increased DOPAC/dopamine ratio can be consid-
ered a sign of enhanced dopaminergic neurotransmission [67,
68]. In earlier studies, DOPAC/dopamine and HVA/dopamine
ratios in striatal and nigral tissue samples were increased in
GDNF-treated animals [66–69], but Hebert et al. reported un-
changed dopamine turnover in GDNF-treated rats [24]. Apart
from enhanced dopaminergic neurotransmission, the in-
creased DOPAC/dopamine turnover after MANF treatment
can be a consequence of augmented tonic release of dopamine
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outside the stimulus responses. As the metabolism of dopa-
mine is efficient, increased amount of extracellular dopamine
might lead to the higher turnover ratio.
Interestingly, we saw a significantly reduced DOPAC/HVA
ratio in GDNF-treated rats at 1 week after the NTF injection
(Fig. 3c). To further elucidate this phenomenon, we tested the
possible effect of GDNF on the activity of the dopamine-
metabolizing enzymes COMT, MAO-A, and MAO-B. GDNF
significantly increased total COMT activity and decreased
MAO-A activity in the striatum when compared to the vehicle,
giving a logical explanation for the reduced DOPAC/HVA ratio
(Fig. 4b, c). Helkamaa et al. have demonstrated that LPS-
induced microglia activation results in increased COMT activ-
ity in the rat brain [70]. In the present study, however, microglia
activation due to surgical procedures cannot explain the in-
creased activity of COMT in GDNF-injected rats, because the
vehicle injection did not cause any changes in total COMT
activity when compared to the non-injected side (Fig. 4b).
Consequently, GDNF seems to have a direct increasing effect
on COMT activity or expression or both.
One possible factor behind the divergent effects of the
NTFs on dopamine neurochemistry seen in our experiments
can be their different diffusion properties within brain paren-
chyma. Volume of distribution of GDNF in the brain is limited
by its high affinity binding to heparan sulfate proteoglycans in
the extracellular matrix and cell surfaces [71]. CDNF and
especially MANF, on the other hand, have shown to have
better diffusion properties in the rat brain when compared to
GDNF [14, 15]. Thus, efficient distribution of MANF in the
striatummay explain its more pronounced effect on dopamine
release. Another explanation for the divergent effects can be
different production methods of the NTFs. GDNF was pro-
duced in E. coli bacterial cells, CDNF in Sf9 insect cells and
MANF in CHO mammalian cells. Proteins produced in bac-
terial cells are not glycosylated after the translation whereas
proteins produced in insect or mammalian cells can be glyco-
sylated. Glycosylation may affect the activity and diffusion
properties of the proteins in the brain. However, non-
glycosylated GDNF produced in E. coli has been shown to
have full biological activity [8]. According to our mass spec-
trometer analysis neither CDNF nor MANF used here were
glycosylated making them comparable with the GDNF of
bacterial origin. Nevertheless, it can be speculated that recom-
binant NTFs produced in mammalian cells may have stronger
biological activity than NTFs produced in other cell lines [72].
MANF and CDNF have been proposed to work under the
condition of ER stress or inflammation [38–41]. The microdi-
alysis protocol used here indeed causes ER stress and inflam-
mation due to mechanical damage around the sampling site.
The damage also results in local degeneration of nerve termi-
nals, edema, changes in bloodstream, and gliosis around the
probe membrane [73]. Repeated insertion and removal of the
probe may affect the results of the second microdialysis due to
pathological changes around the perfusion area; glial scar
forms a diffusion barrier for the analytes which may explain
the general decline in the baseline analyte concentrations 3
versus 1 week after the NTF injection (Table 1). The activation
of MANF and CDNF in ER stress conditions might be a part
of the explanation why they had different effects than GDNF
in this study setting. In addition, the mechanical damage
caused by the implantation of the guide cannula right after
the NTF injection causes an inevitable disruption of the
blood-brain barrier. Due to this disruption, antibodies neutral-
izing exogenous NTFs may invade into the brain abolishing
part of the effect of the NTFs and causing unexpected varia-
tion to the results.
To this day, the cornerstone of the treatment of PD has been
pharmacological substitution of striatal dopamine with initial-
ly good efficacy, but no effect on disease progression. NTFs
are regarded as the first potential disease modifying therapy
for PD as they are able to halt the progression of neurodegen-
eration and restore aberrant neuronal function in various ex-
perimental settings. However, clinical trials with NTFs show
conflicting results. Therefore, it is important to better under-
stand the effects of NTFs on dopaminergic functions of non-
lesioned brain. Our current results reveal divergent biological
effects of exogenously administrated GDNF, CDNF, and
MANF. MANF is able to potentiate stimulus-evoked dopami-
nergic neurotransmission and enhance dopamine turnover in
the brain of freely-moving rats. GDNF, on the other hand,
increases the activity of TH and COMT and decreases the
activity of MAO-A. This study gives an insight into the
long-lasting changes in dopamine synthesis, release and me-
tabolism after a single intrastriatal NTF injection which is
highly relevant information for the development of novel ther-
apeutic strategies for neurodegenerative diseases. However,
further studies are needed to clarify the cellular mechanisms
by which the NTFs produce their effects on neuronal homeo-
stasis seen in this study.
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